Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Denali Therapeutics Announces Pricing of Public Offering of Common Stock

Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 7,826,087 shares of its common stock at a price to the public of $23.00 per share. All of the...

JPM : 134.43 (+1.82%)
DNLI : 24.84 (-11.22%)
AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study

AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.

LLY : 139.26 (+0.69%)
AVEO : 0.53 (-12.06%)
PDLI : 3.23 (unch)
DNLI : 24.84 (-11.22%)
Denali Therapeutics Announces Proposed Offering of Common Stock

Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of $150 million of shares of its common stock. In...

JPM : 134.43 (+1.82%)
DNLI : 24.84 (-11.22%)
Axsome (AXSM) Completes Patient Randomization in TRD Study

Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.

PDLI : 3.23 (unch)
EPZM : 21.81 (+2.11%)
AXSM : 87.60 (+0.72%)
DNLI : 24.84 (-11.22%)
Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance

The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.

PDLI : 3.23 (unch)
EPZM : 21.81 (+2.11%)
EVOK : 1.48 (+3.50%)
DNLI : 24.84 (-11.22%)
Novavax Rises on Fast Track Designation to Influenza Vaccine

The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.

SNY : 48.27 (+1.05%)
EXAS : 90.71 (+3.16%)
NVAX : 7.17 (-15.65%)
DNLI : 24.84 (-11.22%)
Perrigo (PRGO) Rises on Stellar Q419 Preliminary Results

Perrigo (PRGO) announces better-than-expected preliminary results for fourth-quarter 2019 as well as the full year. Shares gain.

PRGO : 59.52 (+1.47%)
EXAS : 90.71 (+3.16%)
DNLI : 24.84 (-11.22%)
PETQ : 30.30 (+0.07%)
Denali Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Denali Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

DNLI : 24.84 (-11.22%)
Emergent (EBS) Posts Preliminary '19 Results, Gives 2020 View

Emergent (EBS) narrows revenue view for 2019 and expects a consistent rise in Narcan nasal spray sales during 2020.

SNY : 48.27 (+1.05%)
GSK : 46.80 (+0.69%)
EBS : 55.75 (+4.13%)
DNLI : 24.84 (-11.22%)
Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a...

AXLA : 5.21 (-0.57%)
DNLI : 24.84 (-11.22%)
EVLO : 7.06 (+4.13%)
KLDO : 8.31 (-9.67%)
MRNA : 22.36 (-1.67%)
RUBY : 8.07 (+1.25%)
MCRB : 3.22 (unch)
SYRS : 7.26 (unch)
Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently served as Senior Vice President,...

BMY : 64.81 (+1.74%)
AXLA : 5.21 (-0.57%)
DNLI : 24.84 (-11.22%)
EVLO : 7.06 (+4.13%)
KLDO : 8.31 (-9.67%)
MRNA : 22.36 (-1.67%)
RUBY : 8.07 (+1.25%)
MCRB : 3.22 (unch)
SYRS : 7.26 (unch)
Options Traders Expect Huge Moves in Denali (DNLI) Stock

Investors need to pay close attention to Denali (DNLI) stock based on the movements in the options market lately.

DNLI : 24.84 (-11.22%)
Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros Pharmaceuticals (NASDAQ: SYRS), a company that...

AXLA : 5.21 (-0.57%)
DNLI : 24.84 (-11.22%)
EVLO : 7.06 (+4.13%)
KLDO : 8.31 (-9.67%)
MRNA : 22.36 (-1.67%)
RUBY : 8.07 (+1.25%)
MCRB : 3.22 (unch)
SYRS : 7.26 (unch)
Flagship Pioneering Appoints Prakash Raman, Ph.D. as Senior Partner and Chief Business Development Officer

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Prakash Raman, Ph.D. to the post of Senior Partner and the newly created role of Chief Business Development...

NVS : 95.54 (+1.96%)
AXLA : 5.21 (-0.57%)
DNLI : 24.84 (-11.22%)
EVLO : 7.06 (+4.13%)
KLDO : 8.31 (-9.67%)
MRNA : 22.36 (-1.67%)
RUBY : 8.07 (+1.25%)
MCRB : 3.22 (unch)
SYRS : 7.26 (unch)
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 9.43% and 25.24%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?...

DNLI : 24.84 (-11.22%)
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -32.61% and -7.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?...

DNLI : 24.84 (-11.22%)
Denali Therapeutics is Now Oversold (DNLI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

DNLI : 24.84 (-11.22%)
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Lags Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -10.81% and -67.35%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?...

DNLI : 24.84 (-11.22%)
Analysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out for

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DNLI : 24.84 (-11.22%)
Denali Therapeutics Inc. (DNLI) Q4 Earnings and Revenues Surpass Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 4050.00% and 1191.24%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the...

DNLI : 24.84 (-11.22%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +2.63 , SEDG +7.11 , THC +1.13 , TER +1.66 , LITE +1.85
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar